Enhancing fertility treatment through advanced non-invasive preimplantation genetic testing for aneuploidy (niPGT-A)

This project will introduce a non-invasive method for selecting embryos with the highest potential for successful pregnancy. Currently, embryo selection largely relies on morphological evaluation, which is not a reliable indicator of chromosomal normality. Our approach leverages recent discoveries that fertilized eggs release DNA into their culture medium. By analyzing this DNA with advanced molecular techniques, we can assess the chromosomal makeup of embryos without the need for biopsy. Our innovative non-invasive PGT-A (niPGT-A) could significantly reduce the physical and emotional strain on women undergoing IVF, decrease the need for repeated treatments, and lower overall treatment costs. This method has the potential to improve the IVF success rate by better identifying viable embryos, thus reducing unwanted abortions and the emotional and financial burden associated with repeated IVF cycles. By differentiating DNA origins — whether from the trophoblast (which becomes the placenta) or the inner cell mass (which develops into the embryo) — we anticipate establishing a correlation that enhances our understanding and implementation of niPGT-A. This project not only aims to optimize reproductive outcomes but also addresses social and economic disparities in reproductive health, making IVF more accessible and equitable. If successful, our findings could shift IVF practices globally towards a less invasive, more cost-effective approach, benefiting more clinics and couples facing fertility issues. This could lead to a paradigm shift in how embryos are assessed, significantly impacting the IVF industry by providing a gentler, more affordable, and optimized treatment alternative.

In collaboration with Steen Broch Laursen from IVF-Syd and Marie Louise Grøndahl at Herlev and Gentofte Hospital

Financed by Danish Life Science Cluster Videnbro grant.